Chimerix Inc. (NASDAQ:CMRX) Insider M Michelle Berrey purchased 14,065 shares of Chimerix stock in a transaction dated Tuesday, May 27th. The shares were purchased at an average price of $14.22 per share, with a total value of $200,004.30. Following the transaction, the insider now directly owns 83,271 shares in the company, valued at approximately $1,184,114. Chimerix Inc. (NASDAQ:CMRX) weekly performance is 7.59%. On last trading day company shares ended up $20.99. Analysts mean target price for the company is $31.67. Chimerix Inc. (NASDAQ:CMRX) distance from 50-day simple moving average (SMA50) is 7.50%.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, on 6 may announced its unaudited financial results for the first quarter ended March 31, 2014. ACADIA reported a net loss of $17.8 million, or $0.19 per common share, for the first quarter of 2014 compared to a net loss of $6.1 million, or $0.08 per common share, for the first quarter of 2013. The net losses for the first quarters of 2014 and 2013 included $3.2 million and $582,000, respectively, in non-cash, stock-based compensation expense. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares advanced 5.16% in last trading session and ended the day on $21.20. ACAD return on assets is -20.50%.ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) quarterly performance is -25.74%.
Advaxis, Inc. (NASDAQ:ADXS) announced the publication of preclinical research with its lead candidate, ADXS-HPV for the treatment of HPV-associated cancers in the journal, Cancer Immunology Research. In this publication, researchers at the National Cancer Institute (NCI) reported on the biologic mechanisms behind the unique ability of ADXS-HPV to decrease the immunosuppressive activity of Tregs in the tumor microenvironment that result in increased anti-tumor activity. Advaxis, Inc. (NASDAQ:ADXS) shares moved up 6.56% in last trading session and was closed at $3.25, while trading in range of $3.20 – $3.53. Advaxis, Inc. (NASDAQ:ADXS) year to date (YTD) performance is -23.35%.
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)’s Chief Executive Officer D Marc Beer has acquired 10,000 shares of common stock, at an average price of $30.12 per share. These shares were purchased in multiple transactions at prices ranging from $29.88 to $30.81. Following these transactions, Mr. Beer has 69,400 direct shares at this $950 million market cap biopharmaceutical company, and owns as well another 246,462 shares, through several indirect holdings. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) ended the last trading day at $33.04. Company weekly volatility is calculated as 8.08% and price to cash ratio as 8.34.Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) showed a positive weekly performance of 2.20%.
On June 3, 2014, NanoString Technologies, Inc. (NASDAQ:NSTG) issued a press release announcing it had entered into a companion diagnostics collaboration with Celgene Corporation under which the Company will support the development of Celgene’s Revlimid for the treatment of Diffuse Large B-cell Lymphoma by developing an in vitro diagnostic assay that is intended to be used to enroll patients in a Phase III study of Revlimid for the treatment of a specific subtype of DLBCL. NanoString Technologies Inc. (NASDAQ:NSTG) weekly performance is -0.77%. On last trading day company shares ended up $15.48. Analysts mean target price for the company is $23.00. NanoString Technologies Inc. (NASDAQ:NSTG) distance from 50-day simple moving average (SMA50) is -6.15%.